Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE

DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE

Standard Dose
50MG;300MG;25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 215187 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE Form and strength TABLET; ORAL - 50MG;300MG;25MG Sponsor LUPIN PHARMS Submission history Latest submission status date: 2023-07-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 215187 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE Form and strength TABLET; ORAL - 50MG;300MG;25MG Sponsor LUPIN PHARMS Submission history Latest submission status date: 2023-07-18 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.